Tejara Capital Ltd holds 5.3% of Cardiol Therapeutics, representing 6,382,551 Class A common shares. The ownership is reported as passive, meaning the securities were acquired in the ordinary course and not to change or influence control of Cardiol Therapeutics.
Key Highlights
- Tejara Capital Ltd is described as a Fund Manager authorised by the FCA in UK.
- The reported fund, Trefoil Select Funds SPC-Stylus SP, is registered in Cayman.
- Tejara Capital Ltd reports a 5.3% ownership position in Cardiol Therapeutics.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. Tejara Capital Ltd reports ownership of 5.3% of Cardiol Therapeutics, equal to 6,382,551 Class A common shares.
Passive Ownership Report Details
The amended Schedule 13G/A identifies Trefoil Select Funds SPC-Stylus SP as the fund connected with the position. Tejara Capital Limited is described as the fund manager, with the fund registered in Cayman and the manager based in the United Kingdom. The record also identifies the fund’s correspondence arrangements through Apex Funds Services Cayman Ltd in Grand Cayman. Tejara’s listed address is in London. It also includes an undertaking to provide requested information that otherwise would be disclosed in a Schedule 13D. Miyan Mansur Mannan signed the certification as DIRECTOR on September 23, 2026.
FAQs
Q: How much of Cardiol Therapeutics does Tejara Capital own?
A: Tejara Capital Ltd reports a 5.3% ownership position in Cardiol Therapeutics. The position consists of 6,382,551 Class A common shares.
Q: Is Tejara Capital’s Cardiol Therapeutics stake active or passive?
A: The ownership is reported as passive. Tejara Capital certified that the securities were held in the ordinary course and not to influence control of Cardiol Therapeutics.
Q: Which fund is connected to Tejara Capital’s Cardiol Therapeutics position?
A: The position is connected with Trefoil Select Funds SPC-Stylus SP. The fund is identified as registered in Cayman, with Tejara Capital Limited serving as its manager.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.